Skip to content
Try Mental Wellness – Lifestyle
Author:
Viatris Inc.
Viatris Reports Third-Quarter 2026 Financial Results
November 5, 2026
Viatris Announces Quarterly Dividend
November 4, 2026
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
October 30, 2026
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
October 16, 2026
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
October 8, 2026
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
October 5, 2026
Viatris Recognized by Forbes as One of the World’s Best Employers for the Sixth Consecutive Year
September 29, 2026
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
September 16, 2026
Viatris Reports Second-Quarter 2026 Financial Results
August 6, 2026
Viatris Announces Quarterly Dividend
August 4, 2026
1
2
Next Page
→